Cyclacel Pharmaceuticals, Inc.
CYCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $2 | $8 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $2 | $8 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -89.8% | – | – | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -27,902.3% | -6,052.9% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -26,074.4% | -5,370.2% | – | – |
| EPS Diluted | -1.36 | -28.67 | -28.5 | -32.1 |
| % Growth | 95.3% | -0.6% | 11.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |